Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R21) | Apply Online

Opportunity Summary:

The NIH funding opportunity PA 08 144, titled "Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R21)," was a discretionary grant program designed to push forward early-stage, exploratory work on mitochondrial biomarkers in cancer. The core aim was to encourage research that develops and validates new mitochondria-related markers that could be useful across the cancer control spectrum, including early detection, diagnostic classification, prognosis, risk assessment, and gauging how patients respond to preventive or symptom-improving (ameliorative) interventions. In practical terms, the FOA was looking for projects that connect measurable mitochondrial signals to clinically meaningful cancer outcomes, with an emphasis on biomarker discovery and initial validation rather than large, definitive clinical trials.

This announcement used the NIH Exploratory/Developmental Grant mechanism (R21), which generally supports innovative, higher-risk ideas that are not yet ready for a full-scale research project grant. The R21 format is typically used when investigators need to generate feasibility data, establish proof-of-concept, refine assays, or demonstrate that a mitochondrial biomarker can be measured reliably and linked to a cancer-relevant endpoint. NIH also noted that this R21 ran in parallel with a scientifically matched R01 opportunity (PA 08 143), meaning investigators could choose between a smaller, exploratory path (R21) and a more extensive, hypothesis-driven path (R01) depending on the maturity and scale of their research plan.

The funding details reflected the flexible, proposal-driven nature of the program. The award ceiling listed for this opportunity was $200,000, and NIH did not commit to a set number of awards. Instead, awards were explicitly contingent on available funds and on the volume and quality of meritorious applications received. NIH also made clear that both the size and duration of awards could vary from project to project because proposed research scopes and budgets could differ substantially. No cost sharing or matching requirement was expected, which is typical for many NIH research grants and lowers barriers for institutions that may not have discretionary funds to contribute.

Eligibility was broad and inclusive, spanning many sectors that contribute to biomedical research. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, state governments, small businesses, nonprofit organizations with or without 501(c)(3) status (other than universities), and for-profit organizations other than small businesses. The announcement also allowed additional categories, including eligible federal agencies, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This wide eligibility signals NIH interest in encouraging mitochondrial biomarker innovation from academic labs, clinical and public health groups, and industry or biotech settings, including international collaborators.

From an administrative standpoint, the opportunity was posted on April 11, 2008, with a creation date listed as December 5, 2008. The original and current closing date were both May 7, 2011, and the archive date was June 7, 2011, indicating the FOA is no longer active but remains available for reference. The sponsoring agency was the National Institutes of Health, and the program aligned with multiple cancer-related CFDA categories, including cancer cause and prevention research (93.393), detection and diagnosis (93.394), treatment (93.395), biology (93.396), and control (93.399). For technical issues accessing the announcement, NIH listed the Office of Extramural Research (OER) webmaster contact (FBOWebmaster@OD.NIH.GOV) and provided the full announcement link hosted on the NIH grants guide website.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Science Education Drug Abuse Partnership Award R25

Previous opportunity: Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 08 144

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 08 144) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 144", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.